Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Impel Pharmaceuticals Inc (IMPL)

Impel Pharmaceuticals Inc (IMPL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 956
  • Shares Outstanding, K 23,900
  • Annual Sales, $ 12,650 K
  • Annual Income, $ -106,310 K
  • EBIT $ -72 M
  • EBITDA $ -70 M
  • 60-Month Beta 1.17
  • Price/Sales 0.10
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -3.13
  • Most Recent Earnings $-0.58 on 11/14/23
  • Next Earnings Date 11/13/23
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.97
  • Growth Rate Est. (year over year) +103,089.69%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0212 +88.68%
on 12/20/23
1.0600 -96.23%
on 11/22/23
-0.2621 (-86.76%)
since 11/20/23
3-Month
0.0212 +88.68%
on 12/20/23
1.0600 -96.23%
on 11/22/23
-0.5010 (-92.61%)
since 09/20/23
52-Week
0.0212 +88.68%
on 12/20/23
4.2000 -99.05%
on 01/04/23
-3.1300 (-98.74%)
since 12/20/22

Most Recent Stories

More News
Cellarity Strengthens Executive Leadership Team

Cellarity , a life sciences company founded by Flagship Pioneering to transform the way medicines are discovered, announced today the appointments of John Leaman, M.D., M.B.A., as Chief Financial Officer...

IMPL : 0.0400 (-27.27%)
SELB : 0.8812 (-8.00%)
MDGN : 5.57 (+3.15%)
DNLI : 24.22 (-0.82%)
EVLO : 0.0005 (-66.67%)
FHTX : 7.72 (-1.78%)
MRNA : 38.25 (+3.55%)
OMGA : 0.7760 (-1.80%)
SANA : 2.35 (-7.11%)
MCRB : 0.7318 (-10.09%)
Impel Pharmaceuticals to Participate in 2022 Wedbush PacGrow Healthcare Conference

SEATTLE, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative...

IMPL : 0.0400 (-27.27%)
Impel Pharmaceuticals Announces First Patient Dosed in Phase 2a Study Evaluating INP105 to Treat Acute Agitation in Adolescents With Autism Spectrum Disorder (ASD)

CALM 201 Study to Explore the Safety and Efficacy of Single 5mg-Dose INP105 Compared to Placebo in Quickly Reducing Agitation in Participants with ASD ...

IMPL : 0.0400 (-27.27%)
Impel Pharmaceuticals to Present Trudhesa® Data at the 64th Annual Meeting of the American Headache Society

Oral Presentation Showcases Early Ability to Predict Responders to Trudhesa New Analysis Suggest Patient-Reported Benefits of Long-Term Use with Trudhesa ...

IMPL : 0.0400 (-27.27%)
Impel Pharmaceuticals To Present At The JMP Securities Life Sciences Conference

SEATTLE, June 08, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative...

IMPL : 0.0400 (-27.27%)
Impel Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update

Trudhesa® Continues Strong Launch Trajectory with Q1 2022 TRx Growth of 111% vs. Q4 2021 Planned initiation of INP105 Proof-of-Concept Study for Autism...

IMPL : 0.0400 (-27.27%)
Impel Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference

SEATTLE, May 12, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative...

IMPL : 0.0400 (-27.27%)
Impel Pharmaceuticals to Report First Quarter 2022 Financial Results on Monday, May 16, 2022

SEATTLE, May 09, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative...

IMPL : 0.0400 (-27.27%)
Impel Neuropharma Announces Company Will Now Be Known as Impel Pharmaceuticals to Reflect Corporate Transformation

Impel Celebrates Its One-Year Anniversary as a Public Company Today at the Nasdaq Stock Market Closing Bell Ceremony Starting at 3:45 p.m. EDT...

IMPL : 0.0400 (-27.27%)
Impel NeuroPharma To Present At The 21st Annual Needham Healthcare Conference

SEATTLE, April 07, 2022 (GLOBE NEWSWIRE) -- Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative...

IMPL : 0.0400 (-27.27%)

Business Summary

Impel NeuroPharma Inc. is a late-stage pharmaceutical company. It is focused on utilizing its proprietary technology to develop and commercialize transformative therapies for patients suffering from diseases with high unmet medical needs. Impel NeuroPharma Inc. is based in SEATTLE.

See More

Key Turning Points

3rd Resistance Point 0.0817
2nd Resistance Point 0.0659
1st Resistance Point 0.0529
Last Price 0.0400
1st Support Level 0.0241
2nd Support Level 0.0083
3rd Support Level N/A

See More

52-Week High 4.2000
Fibonacci 61.8% 2.6037
Fibonacci 50% 2.1106
Fibonacci 38.2% 1.6175
Last Price 0.0400
52-Week Low 0.0212

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar